MCID: AND014
MIFTS: 44

Androgenic Alopecia

Categories: Skin diseases

Aliases & Classifications for Androgenic Alopecia

MalaCards integrated aliases for Androgenic Alopecia:

Name: Androgenic Alopecia 12 15 32
Androgenetic Alopecia 12 71
Alopecia Androgenetica, Male Pattern Baldness 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050801
ICD10 32 L64 L64.9
UMLS 71 C0162311

Summaries for Androgenic Alopecia

Disease Ontology : 12 An alopecia that is characterized by M-shaped hair line recession and thinning of hair at the crown of the head in males.

MalaCards based summary : Androgenic Alopecia, also known as androgenetic alopecia, is related to alopecia, androgenetic, 1 and prostatic hypertrophy. An important gene associated with Androgenic Alopecia is SHBG (Sex Hormone Binding Globulin), and among its related pathways/superpathways are Endometrial cancer and Metabolism of steroid hormones. The drugs Ethanol and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include prostate, skin and ovary, and related phenotypes are endocrine/exocrine gland and nervous system

Wikipedia : 74 Pattern hair loss is hair loss that primarily affects the top and front of the scalp. In male-pattern... more...

Related Diseases for Androgenic Alopecia

Diseases related to Androgenic Alopecia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 232)
# Related Disease Score Top Affiliating Genes
1 alopecia, androgenetic, 1 33.0 SRD5A2 SRD5A1 SHBG CYP19A1 AR
2 prostatic hypertrophy 30.7 SRD5A1 KLK3 CYP19A1 AR
3 psychosexual disorder 30.7 SHBG PRL
4 galactorrhea 30.5 PRL IGF1
5 prostatic hyperplasia, benign 30.4 SRD5A2 SRD5A1 SHBG KLK3 AR
6 prostate disease 30.4 SRD5A2 SRD5A1 KLK3 CYP19A1 AR
7 telogen effluvium 30.3 SRD5A2 LPP EDA2R ANTXR2
8 gynecomastia 30.3 SRD5A2 SRD5A1 SHBG PRL KLK3 CYP19A1
9 prostatic adenoma 30.2 SRD5A1 KLK3
10 sexual disorder 30.1 SHBG PRL KLK3 INS AR
11 neurofibromatosis, type ii 30.0 SRD5A1 SHBG PRL INS IGF1
12 insulin-like growth factor i 30.0 SHBG PRL INS IGF1
13 impotence 29.9 SRD5A1 SHBG PRL KLK3 INS AR
14 alopecia 29.8 SRD5A2 SRD5A1 SHBG PRL KRT86 KRT15
15 lipoid congenital adrenal hyperplasia 29.8 SRD5A1 SHBG PRL INS CYP19A1
16 hyperprolactinemia 29.7 SHBG PRL INS IGF1
17 premature ovarian failure 1 29.6 SHBG PRL INS IGF1 CYP19A1 AR
18 ovarian disease 29.6 SHBG PRL INS IGF1 CYP19A1 AR
19 hyperandrogenism 29.5 SRD5A1 SHBG PRL INS IGF1 CYP19A1
20 polycystic ovary syndrome 29.5 SRD5A1 SHBG PRL INS IGF1 CYP19A1
21 hypogonadism 29.4 SHBG PRL KLK3 INS IGF1 CYP19A1
22 hair disease 29.3 SHBG LPP KRT86 KRT15 INS IGF1
23 body mass index quantitative trait locus 11 29.1 SHBG PRL INS IGF1 CYP19A1 AR
24 prostate cancer 27.9 SRD5A2 SRD5A1 SHBG KLK3 INS IGF1
25 marie unna congenital hypotrichosis 11.5
26 hypotrichosis 1 11.4
27 hypotrichosis simplex 11.4
28 47, xxy 10.5 SHBG AR
29 frontal fibrosing alopecia 10.5
30 inhibited female orgasm 10.5 SHBG PRL
31 prostate adenoid cystic carcinoma 10.5 KLK3 AR
32 prostate leiomyoma 10.5 KLK3 AR
33 submandibular gland cancer 10.5 KLK3 AR
34 prostatic acinar adenocarcinoma 10.5 KLK3 AR
35 postmenopausal atrophic vaginitis 10.5 SHBG CYP19A1
36 hypoactive sexual desire disorder 10.4 SHBG CYP19A1
37 rapidly involuting congenital hemangioma 10.4
38 luteoma 10.4 SHBG PRL CYP19A1
39 estrogen excess 10.4 SHBG PRL CYP19A1
40 pelvic varices 10.4 SHBG PRL KLK3
41 hermaphroditism 10.4 SRD5A2 SHBG AR
42 pseudovaginal perineoscrotal hypospadias 10.4 SRD5A2 SRD5A1 AR
43 hypospadias 10.4 SRD5A2 SRD5A1 AR
44 breast cyst 10.4 PRL KLK3 CYP19A1
45 varicocele 10.4 SHBG PRL AR
46 transsexualism 10.4 SRD5A2 CYP19A1 AR
47 prostate neuroendocrine neoplasm 10.3 KLK3 AR
48 coronary heart disease 1 10.3
49 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 10.3
50 diffuse alopecia areata 10.3

Graphical network of the top 20 diseases related to Androgenic Alopecia:



Diseases related to Androgenic Alopecia

Symptoms & Phenotypes for Androgenic Alopecia

MGI Mouse Phenotypes related to Androgenic Alopecia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.91 AR CYP19A1 HR IGF1 INS PRL
2 nervous system MP:0003631 9.9 AR CD200 CYP19A1 DKK1 EFNA3 FGF7
3 renal/urinary system MP:0005367 9.5 AR CYP19A1 DKK1 FGF7 HR IGF1
4 reproductive system MP:0005389 9.36 ANTXR2 AR CYP19A1 FGF7 HR IGF1

Drugs & Therapeutics for Androgenic Alopecia

Drugs for Androgenic Alopecia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2 Anti-Infective Agents Phase 4
3 Central Nervous System Depressants Phase 4
4 Anti-Infective Agents, Local Phase 4
5 Fenugreek seed meal Phase 4
6 Fenugreek Phase 4
7
Dutasteride Approved, Investigational Phase 3 164656-23-9 152945 6918296
8 Pharmaceutical Solutions Phase 3
9
Nitric Oxide Approved Phase 1, Phase 2 10102-43-9 145068
10
Bimatoprost Approved, Investigational Phase 2 155206-00-1 5311027
11
Acetylcholine Approved, Investigational Phase 2 51-84-3 187
12
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
13
Vitamin C Approved, Nutraceutical Phase 1, Phase 2 50-81-7 5785 54670067
14
Maleic acid Experimental, Investigational Phase 1, Phase 2 110-17-8, 110-16-7 444972
15 Adjuvants, Immunologic Phase 2
16 Protective Agents Phase 1, Phase 2
17 Ammonium trichloro(dioxoethylene-O,O'-)tellurate Phase 2
18 Antiviral Agents Phase 2
19 Radiation-Protective Agents Phase 2
20 Antioxidants Phase 1, Phase 2
21 Anti-Asthmatic Agents Phase 1, Phase 2
22 Respiratory System Agents Phase 1, Phase 2
23 Free Radical Scavengers Phase 1, Phase 2
24 Autonomic Agents Phase 1, Phase 2
25 Bronchodilator Agents Phase 1, Phase 2
26
protease inhibitors Phase 2
27 HIV Protease Inhibitors Phase 2
28 Proteasome Inhibitors Phase 2
29 Androgens Phase 2
30 Neurotransmitter Agents Phase 2
31 Acetylcholine Release Inhibitors Phase 2
32 Botulinum Toxins Phase 2
33 Cholinergic Agents Phase 2
34 abobotulinumtoxinA Phase 2
35 Botulinum Toxins, Type A Phase 2
36 Ophthalmic Solutions Phase 2
37 Tranquilizing Agents Phase 2
38 GABA Agents Phase 2
39 Anticonvulsants Phase 2
40 Antimanic Agents Phase 2
41 Psychotropic Drugs Phase 2
42 Immunologic Factors Phase 1, Phase 2
43 Mitogens Phase 1, Phase 2
44 Immunosuppressive Agents Phase 1, Phase 2
45 Complement System Proteins Phase 1, Phase 2
46 Complement Inactivating Agents Phase 1, Phase 2
47 Complement Factor H Phase 1, Phase 2
48
Methyltestosterone Approved Phase 1 58-18-4 6010
49
Testosterone undecanoate Approved, Investigational Phase 1 5949-44-0
50
Testosterone enanthate Approved Phase 1 315-37-7 9416

Interventional clinical trials:

(show top 50) (show all 119)
# Name Status NCT ID Phase Drugs
1 Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial Unknown status NCT02999737 Phase 4
2 Minoxidil in Treatment of Androgenetic Alopecia Completed NCT04090801 Phase 4 Topical minoxidil 5% in 90% ethanol and 5% propylene glycol;Topical minoxidil 5% in pure ethanol alone
3 Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
4 the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial Recruiting NCT03388840 Phase 4
5 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
6 BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA Unknown status NCT01655108 Phase 3 Minoxidil;Saline
7 An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V) Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
8 A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
9 A Prospective, Randomized, Controlled, Double-Blind Study That Evaluates the Safety and Efficacy of Three Active REVIAN Caps Versus a Non-Active REVIAN Cap (Sham) in Participants With Pattern Hair Loss (Androgenic Alopecia) Completed NCT04019795 Phase 3
10 A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
11 Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume Completed NCT00958750 Phase 3 minoxidil
12 Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
13 Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
14 A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness Completed NCT03004469 Phase 3 P-3074;Finasteride;P-3074 Vehicle;Finasteride Placebo
15 A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
16 A Double-Blind, Randomized, Placebo-Controlled Trial of the Efficacy and Safety of 5 Percent Minoxidil Foam in the Treatment of Androgenetic Alopecia in Males Completed NCT00151515 Phase 3 minoxidil
17 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia) Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
18 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625) Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
19 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia Recruiting NCT03742518 Phase 2, Phase 3 Topical SM04554 solution;Topical SM04554 solution;Topical vehicle solution
20 A Double-Blind, Randomized, Clinical Trial of the Efficacy and Safety Study to Compare Topical Herbal Solution and Minoxidil 5% in Healthy Male Subjects With Androgenetic Alopecia Active, not recruiting NCT03753113 Phase 3 Topical Minoxidil 5%
21 Phase 2 Study of Topical AS101 for the Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women Unknown status NCT00418249 Phase 2 AS101
22 A Phase 2 Multicenter, Randomized, Placebo-Controlled, Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men Unknown status NCT00471510 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
23 A Multi-center, Randomized, Controlled, Double-blind Study That Evaluates a Low Level Laser Therapy Over-the-counter at Home Device, Theradome™ LH80 PRO vs a Sham Device, for Promoting Hair Growth in Males Diagnosed With Androgenetic Alopecia Unknown status NCT02528552 Phase 2
24 A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment Of Androgenetic Alopecia (AGA) Unknown status NCT01643629 Phase 1, Phase 2
25 The Clinical Effects of HSC (Hair Stimulating Complex) on Hair Growth in Androgenetic Alopecia: A Phase I/II Clinical Trial Unknown status NCT01501617 Phase 1, Phase 2
26 An Efficacy and Safety Pilot Study Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Treatment of AGA Unknown status NCT01650272 Phase 1, Phase 2 5% MInoxidil milky lotion;5% Minoxidil solution
27 A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate Safety & Efficacy Of Autologous Human Platelet Lysate For Treatment Of Androgenetic Alopecia In Patients Undergoing Hair Transplant Unknown status NCT01644422 Phase 1, Phase 2
28 Safety and Efficacy of Nitric Oxide Gel in Promoting Hair Growth in Male Human Subjects With Androgenetic Alopecia Unknown status NCT01347957 Phase 1, Phase 2
29 Evaluation of the Efficacy of Hcap Formula Nutrition Supplement for Treatment of Men With Androgenic Alopecia: A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT02150187 Phase 2
30 A Single-center, Active-controlled, Randomized, Double-blind, Proof of Concept Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application in Male Patients With Androgenetic Alopecia Completed NCT02280603 Phase 1, Phase 2 DA-4001C;5% minoxidil
31 A Phase 2, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Solution 5%, Minoxidil Solution 5%, and Vehicle Solution, Applied Twice-daily for 26 Weeks in Males With Androgenetic Alopecia (AGA) Completed NCT02279823 Phase 2 CB-03-01 solution;Minoxidil Solution 5%;Placebo solution
32 A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) Completed NCT02275351 Phase 2 SM04554;Vehicle
33 A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing Completed NCT02503137 Phase 2 Topical SM04554 solution;Topical Vehicle solution
34 A Phase 2 Multicenter, Randomized, Placebo- and Comparator-Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia in Men Completed NCT00418730 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
35 A Prospective, Single Center, Open Label, Proof of Principle Study to Assess the Efficacy and Safety of 150 Units of Botulinum Toxin-A Intra-Muscular Injection in the Prevention of Hair Loss in Men With Androgenetic Alopecia Completed NCT00965640 Phase 2 Botulinum Toxin - A injections
36 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males Completed NCT02781311 Phase 2 Setipiprant;Placebo;Finasteride
37 A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) Completed NCT01904721 Phase 2 Bimatoprost Solution 1;Bimatoprost Solution 2;Bimatoprost Vehicle
38 A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells Into the Hair Loss Area of the Scalp of Subjects Completed NCT01451190 Phase 2
39 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Cultured Occipital Autologous Dermal and Epidermal Cells vs Dermal Cells, Where Cells Are Expanded ex Vivo From Plucked Scalp, Into the Hair Loss Area of the Scalp of Subjects. Completed NCT01451177 Phase 2
40 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells Into the Hair Loss Area of the Scalp of Subjects Completed NCT01451151 Phase 2
41 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs Dermal Cells Into the Hair Loss Area of the Scalp of Subjects Completed NCT01451138 Phase 2
42 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Hair Loss Area of the Scalp of Subjects and Synergy With Application of Topical Minoxidil Completed NCT01451125 Phase 2
43 A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Hair Loss Area of the Scalp of Subjects Completed NCT01451112 Phase 2
44 A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451099 Phase 2
45 A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of a 1 Time Injection vs. Repeat Injections of ex Vivo Expanded Cultured Autologous Occipital Dermal and Epidermal Cells (Same Day as Cell Culture Harvest) Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451073 Phase 2
46 A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of Injections of ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451047 Phase 2
47 A Phase 2 Randomized Study to Evaluate and Compare the Efficacy of a 1 Time Injection vs. Repeat Injections of ex Vivo Expanded Cultured Autologous Occipital Dermal and Epidermal Cells (Day After Cell Culture Harvest) Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451021 Phase 2
48 A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of ex Vivo-cultured, Expanded, Occipital Autologous Dermal and Epidermal Cells, Injected Into the Hair Loss Area of the Scalp of Male and Female Subjects With Alopecia Completed NCT01669746 Phase 2
49 Investigator-Initiated, Double Blind, Two-Armed, Placebo-Controlled, Randomized Clinical Trial With an Open-Label Extension Phase, to Investigate Efficacy of 5% Minoxidil Topical Foam Twice Daily in Men With Androgenetic Alopecia in the Temple and Vertex Region Concerning Hair Volume Over 24 / 104 Weeks Completed NCT01319370 Phase 2 Minoxidil;vehicle of 5% Minoxidil topical foam
50 Randomized, Single-centre, Double-blind, Placebo-controlled, Phase I / IIa Study to Evaluate the Safety and Efficacy of Human Autologous Hair Follicle Dermal Sheath Cup Cells (DSCC) in Women and Men With Androgenetic Alopecia. Completed NCT01286649 Phase 1, Phase 2

Search NIH Clinical Center for Androgenic Alopecia

Genetic Tests for Androgenic Alopecia

Anatomical Context for Androgenic Alopecia

MalaCards organs/tissues related to Androgenic Alopecia:

40
Prostate, Skin, Ovary, Breast, Testes, Pituitary, Heart

Publications for Androgenic Alopecia

Articles related to Androgenic Alopecia:

(show top 50) (show all 1720)
# Title Authors PMID Year
1
Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. 61
31733195 2020
2
Exploring the potential of minoxidil tretinoin liposomal based hydrogel for topical delivery in the treatment of androgenic alopecia. 61
31741401 2020
3
Female Androgenetic Alopecia: An Update on Diagnosis and Management. 61
31677111 2020
4
Trichologic response of platelet-rich plasma in androgenetic alopecia is maintained during combination therapy. 61
29580860 2020
5
Cell Enriched Autologous Fat Grafts to Follicular Niche Improves Hair Regrowth in Early Androgenetic Alopecia. 61
32020170 2020
6
Large-Scale Beard Extraction Enhances the Cosmetic Results of Scalp Hair Restoration in Advanced Androgenetic Alopecia in East Asian Men: A Retrospective Study. 61
31784942 2020
7
Autologous Activated Platelet-Rich Plasma (AA-PRP) and Non-activated (A-PRP) in Hair Growth: a retrospective, blinded, randomized evaluation in Androgenetic Alopecia. 61
32011196 2020
8
Fully automated chip-based nanoelectrospray ionization-mass spectrometry as an effective tool for rapid and high-throughput screening of 5α-reductase inhibitors. 61
32008083 2020
9
Ultrasound-activated particles as CRISPR/Cas9 delivery system for androgenic alopecia therapy. 61
31901692 2020
10
'The psychosocial burden of alopecia areata and androgenetica': a cross-sectional multicentre study among dermatological out-patients in 13 European countries. 61
31465592 2020
11
Prolonged use of finasteride-induced gonadal sex steroids alterations, DNA damage and menstrual bleeding in women. 61
31967291 2020
12
Platelet-Rich Plasma and Its Utilities in Alopecia: A Systematic Review. 61
31211715 2020
13
Clinical Efficacy of a Topical Compounded Formulation in Male Androgenetic Alopecia: Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Caffeine Citrate 0.05% Hydroalcoholic Solution. 61
32023218 2020
14
Reply to: "Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation". 61
31520659 2020
15
Randomized trial of electrodynamic microneedle combined with 5% minoxidil topical solution for the treatment of Chinese male Androgenetic alopecia. 61
29028377 2020
16
Growth factor concentrations in platelet-rich plasma for androgenetic alopecia: An intra-subject, randomized, blinded, placebo-controlled, pilot study. 61
31984508 2020
17
Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: A descriptive monocentric study. 61
31820540 2020
18
Do Kimchi and Cheonggukjang Probiotics as a Functional Food Improve Androgenetic Alopecia? A Clinical Pilot Study. 61
31385480 2020
19
Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation. 61
31520662 2020
20
The Clinical Efficacy and Safety of Autologous Activated Platelet-Rich Plasma Injection in Androgenetic Alopecia. 61
32021857 2020
21
Topical ketoconazole for the treatment of androgenetic alopecia: A systematic review. 61
31858672 2020
22
Excellent response to mesotherapy as adjunctive treatment in male androgenetic alopecia. 61
31066492 2020
23
Can we halt male androgenetic alopecia progression without antiandrogenic drugs? 61
31846191 2020
24
Oral Minoxidil: A Possible New Therapy for Androgenetic Alopecia. 61
31994933 2020
25
Androgenetic alopecia is associated with increased scalp hardness. 61
31944388 2020
26
A prospective study examining isolated acne and acne with hyperandrogenic signs in adult females. 61
31868042 2020
27
Erosive pustular dermatosis of the scalp: a multicentre study. 61
31954062 2020
28
Fibrosing Alopecia in a Pattern Distribution. 61
31926219 2020
29
Increased Preauricular Wrinkles in Frontal Fibrosing Alopecia Compared to Age-Matched Controls: A Prospective Study of 64 Patients. 61
32021855 2020
30
Post-finasteride syndrome: a surmountable challenge for clinicians. 61
32033719 2020
31
Consequences of steroid-5α-reductase deficiency and inhibition in vertebrates. 61
31981690 2020
32
Finasteride and Suicide: A Postmarketing Case Series. 61
31935720 2020
33
Standardization of Plasma Rich in Growth Factors (PRGF) and its effects on androgenic hair loss. 61
31838924 2020
34
Platelet sonicates activate hair follicle stem cells and mediate enhanced hair follicle regeneration. 61
31802614 2020
35
Extremely Low-Frequency Electromagnetic Fields Increase the Expression of Anagen-Related Molecules in Human Dermal Papilla Cells via GSK-3β/ERK/Akt Signaling Pathway. 61
31991762 2020
36
Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris. 61
31832993 2019
37
Dilation of Multiple Eccrine Ducts as a Highly Specific Marker for Cicatricial Alopecia. 61
31764231 2019
38
Non-ablative radio frequency for the treatment of androgenetic alopecia. 61
31855270 2019
39
Global expression profile and global genome methylation signatures in male patients with androgenetic alopecia. 61
31876348 2019
40
The effect of platelet-rich plasma injection in the treatment of androgenetic alopecia. 61
30895745 2019
41
Accelerated hair growth by combining thread monofilament and minoxidil in female androgenetic alopecia. 61
31789457 2019
42
Transdermal finasteride delivery via powder-carrying microneedles with a diffusion enhancer to treat androgenetic alopecia. 61
31689460 2019
43
In silico analysis of gene expression data from bald frontal and haired occipital scalp to identify candidate genes in male androgenetic alopecia. 61
31511972 2019
44
A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia. 61
30982177 2019
45
Post-finasteride syndrome - does it really exist? 61
30651009 2019
46
The mechanism of activated platelet-rich plasma supernatant promotion of hair growth by cultured dermal papilla cells. 61
30884113 2019
47
In Vitro and In Vivo Assessment of Metabolic Drug Interaction Potential of Dutasteride with Ketoconazole. 61
31835695 2019
48
[Therapeutic effect of Impatiens balsamina, Lawsonia inermis L. and Henna on androgenetic alopecia in mice]. 61
31852654 2019
49
Alopecia areata multiplex following autologous dermal micrograft injection for treatment of androgenetic alopecia. 61
31120162 2019
50
The diagnosis of androgenetic alopecia in children: Considerations of pathophysiological plausibility. 61
31168786 2019

Variations for Androgenic Alopecia

Expression for Androgenic Alopecia

Search GEO for disease gene expression data for Androgenic Alopecia.

Pathways for Androgenic Alopecia

Pathways related to Androgenic Alopecia according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.62 SRD5A2 KLK3 INS IGF1 AR
2
Show member pathways
11.58 SRD5A2 SRD5A1 CYP19A1
3
Show member pathways
11.43 SRD5A2 SRD5A1 CYP19A1
4 11.38 INS IGF1 FGF7 DKK1
5 11.3 INS IGF1 DKK1
6 11.23 INS IGF1 CYP19A1
7
Show member pathways
11.19 SRD5A2 SRD5A1 KLK3 IGF1 AR
8 11.18 INS IGF1 DKK1
9
Show member pathways
11.1 KLK3 INS AR
10 10.99 IGF1 CYP19A1 AR
11 10.75 SHBG AR

GO Terms for Androgenic Alopecia

Cellular components related to Androgenic Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.28 SHBG PTGDS PRL KLK3 INS IGF1
2 endosome lumen GO:0031904 9.16 PRL INS
3 organelle membrane GO:0031090 9.13 SRD5A2 SRD5A1 CYP19A1

Biological processes related to Androgenic Alopecia according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.93 PRL INS IGF1 FGF7 AR
2 cellular protein metabolic process GO:0044267 9.78 PRL KLK3 INS IGF1
3 cell-cell signaling GO:0007267 9.76 SRD5A2 INS EFNA3 AR
4 male gonad development GO:0008584 9.74 SRD5A2 SRD5A1 AR
5 epidermis development GO:0008544 9.73 KRT15 FGF7 EDA2R
6 steroid biosynthetic process GO:0006694 9.61 SRD5A2 SRD5A1 CYP19A1
7 regulation of protein localization to plasma membrane GO:1903076 9.58 INS AR
8 positive regulation of glycogen biosynthetic process GO:0045725 9.58 INS IGF1
9 regulation of systemic arterial blood pressure GO:0003073 9.55 KLK3 AR
10 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.52 IGF1 AR
11 negative regulation of neuroinflammatory response GO:0150079 9.51 IGF1 CD200
12 androgen biosynthetic process GO:0006702 9.49 SRD5A2 SRD5A1
13 cellular response to testosterone stimulus GO:0071394 9.4 SRD5A1 AR
14 prostate gland growth GO:0060736 9.37 CYP19A1 AR
15 testosterone biosynthetic process GO:0061370 9.32 SRD5A2 CYP19A1
16 female genitalia development GO:0030540 9.26 SRD5A1 CYP19A1
17 androgen catabolic process GO:0006710 9.16 SRD5A1 CYP19A1
18 sex differentiation GO:0007548 9.13 SRD5A2 SRD5A1 AR
19 androgen metabolic process GO:0008209 8.8 SRD5A2 SRD5A1 CYP19A1

Molecular functions related to Androgenic Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.5 PRL INS IGF1
2 insulin-like growth factor receptor binding GO:0005159 9.26 INS IGF1
3 androgen binding GO:0005497 9.16 SHBG AR
4 cholestenone 5-alpha-reductase activity GO:0047751 8.96 SRD5A2 SRD5A1
5 3-oxo-5-alpha-steroid 4-dehydrogenase activity GO:0003865 8.62 SRD5A2 SRD5A1

Sources for Androgenic Alopecia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....